LAMPERTICO, PIETRO
LAMPERTICO, PIETRO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis
2018 E. Degasperi, A. Aghemo, S. Paolucci, R. D'Ambrosio, M. Borghi, R. Perbellini, F. Novazzi, S. De Nicola, G. Lunghi, F. Baldanti, P. Lampertico
2-year effectiveness and safety of Tenofovir in 302 NUC-naive patients with chronic hepatitis B : a multicenter european study in clinical practive
2011 P. Lampertico, R. Soffredini, M. Vigano, C. Yurdaydin, R. Idilman, G. Papatheodoridis, K. Margariti, M. Buti, R. Esteban, S. Zaltron, A. Vavassori, G. Carosi, E. Minola, M. Vinci, G. Pinzello, A. Giorgini, M. Zuin, A. Salmi, P. Del Poggio, F. De Filippi, S. Bruno, L. Pasulo, S. Fagiuoli, M. Andreoletti, A. Colli, F. Maldini, M. Milanese, A. Colombo, G. Bellati, E. Angeli, C. Magni, G. Gubertini, G. Rizzardini, M. Fasano, T. Santantonio, N. Terreni, G. Spinzi, F. Facchetti, F. Invernizzi, A. Testa
2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice
2012 P. Lampertico, R. Soffredini, M. Viganò, C. Yurdaydin, R. Idilman, G.V. Papatheodoridis, K. Margariti, M. Buti, R. Esteban, S. Zaltron, A. Vavassori, G. Carosi, E. Minola, M. Vinci, G. Pinzello, A.M. Giorgini, M. Zuin, A. Salmi, P. Del Poggio, F. De Filippi, S. Bruno, L. Pasulo, S. Fagiuoli, M. Andreoletti, A. Colli, F. Fumagalli Maldini, M. Milanese, A. Colombo, G.A. Bellati, E. Angeli, C.F. Magni, G.A. Gubertini, G. Rizzardini, M. Fasano, T. Santantonio, N.M. Terreni, G. Spinzi, F. Facchetti, F. Invernizzi, M. Colombo
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients
2007 P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, G. Lunghi, E. Del Ninno, M. Colombo
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients
2007 P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, G. Lunghi, E. Del Ninno, M. Colombo
A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B
2018 H.L.Y. Chan, D. Messinger, G.V. Papatheodoridis, M. Cornberg, Q. Xie, T. Piratvisuth, H. Ren, P.T. Kennedy, A. Thompson, A. Caputo, G. Bakalos, V. Pavlovic, P. Lampertico
A drug transporter gene polymorphism predicts renal tubular toxicity in patients with chronic hepatitis B on long-term adefovir and lamivudine combination
2010 M. Viganò, P. Lampertico, P. Dongiovanni, F. Facchetti, L.V.C. Valenti, R. Soffredini, S.R. Fargion, M. Colombo
A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2A in hepatitis B e antigen-negative chronic hepatitis B
2018 P. Lampertico, D. Messinger, M. Cornberg, M. Brunetto, J. Petersen, P. Kennedy, T. Asselah, V. Rothe, A. Caputo, G. Bakalos, V. Pavlovic, G.V. Papatheodoridis
A global scientific strategy to cure hepatitis B
2019 P.A. Revill, F.V. Chisari, J.M. Block, M. Dandri, A.J. Gehring, H. Guo, J. Hu, A. Kramvis, P. Lampertico, H.L.A. Janssen, M. Levrero, W. Li, T.J. Liang, S. Lim, F. Lu, M.C. Penicaud, J.E. Tavis, R. Thimme, F. Zoulim, P. Arbuthnot, P.A. Boonstra, K. Chang, P. Chen, D. Glebe, L.G. Guidotti, J. Fellay, C. Ferrari, L. Jansen, D.T.Y. Lau, A.S. Lok, M.K. Maini, W. Mason, G. Matthews, D. Paraskevis, J. Petersen, B. Rehermann, E. Shin, A. Thompson, F. van Bömmel, F. Wang, K. Watashi, H. Yang, Z. Yuan, M. Yuen, T. Block, V. Miller, U. Protzer, C. Bréchot, S. Locarnini, M.G. Peters, R.F. Schinazi
A multicenter italian study of rescue Adefovir Dipivoxil therapy in Lamivudine resistant patients : a 2-year analysis of 604 patients
2005 P. Lampertico, A. Marzano, M. Levrero, T. Santantonio, P. Andreone, M.R. Brunetto, V. Di Marco, S. Fagiuoli, G. Mazzella, G. Raimondo
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C
2021 S. Varchetta, D. Mele, R. D'Ambrosio, R. Perbellini, A. Lombardi, A. Rojas, S. Paolucci, F. Baldanti, B. Oliviero, S. Mantovani, C. Tinelli, A. De Silvestri, M. Romero Gomez, P. Lampertico, M.U. Mondelli
A prospective study of peripheral blood alpha-fetoprotein messenger RNA in cirrhotic patients at risk of hepatocellular carcinoma
2003 M. Iavarone, P. Lampertico, G. Ronchi, E. Del Ninno, A. Zanella, M. Colombo
A response guided approach to peginterferon alfa-2a therapy based on HBsAg levels at weeks 12 and 24 improves response rates in HBeAG-negative, genotype D chronic hepatitis B patients
2011 P. Lampertico, M. Vigano, G.G. Di Costanzo, E. Sagnelli, M. Fasano, V. Di Marco, S. Boninsegna, P. Farci, S.R. Fargion, T. Giuberti, V. Rothe, L. Regep, B. Massetto, F. Facchetti, A. Testa
A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B
2018 R. El Sharkawy, K. Thabet, P. Lampertico, S. Petta, A. Mangia, T. Berg, M. Metwally, A. Bayoumi, A. Boonstra, W.P. Brouwer, A. Smedile, M.L. Abate, A. Loglio, M.W. Douglas, A. Khan, R. Santoro, J. Fischer, D.J. Leeming, C. Liddle, J. George, M. Eslam
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms
2019 R.E. Sharkawy, A. Bayoumi, M. Metwally, A. Mangia, T. Berg, M. Romero-Gomez, M.L. Abate, W.L. Irving, D. Sheridan, G.J. Dore, U. Spengler, P. Lampertico, E. Bugianesi, M. Weltman, L. Mollison, W. Cheng, S. Riordan, R. Santoro, R. Gallego-Durán, J. Fischer, J. Nattermann, R. D’Ambrosio, D. Mcleod, E. Powell, O. Latchoumanin, K. Thabet, M.A.M. Najim, M.W. Douglas, C. Liddle, L. Qiao, J. George, M. Eslam, R. White, A. Rojas, M. Bassendine, C. Rosso, L. Mezzabotta, R. Leung, B. Malik, G. Matthews, J. Grebely, V. Fragomeli, J.R. Jonsson
Acute hepatitis following assumption of a herbal remedy
2008 M. Viganò, P. Lampertico, M. Colombo
Add on Adefovir prevents the emergence of ADV resistance in Lamivudine-resistant patients : a 4-year study
2008 P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, M. Colombo
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D
2019 P. Lampertico, M.R. Brunetto, A. Craxì, G.B. Gaeta, M. Rizzetto, A. Rozzi, M. Colombo, D. Antonio, P. Andreone, D. Antonio, G. Brancaccio, F. Bronte, L. Bruzzone, G. Caccamo, B. Caccianotti, V. Calvaruso, L. Chessa, M. Ciarallo, B. Coco, P. Colombatto, C. Cursaro, D. D'Aluisio, L. Demelia, V. DI MARCO, D. Dissegna, F. Invernizzi, I. Lenisa, T. Lembo, M. Levrero, V. Marchese, G. Mangia, A. Picciotto, S. Pierconti, D. Antonio, G. Raimondo, C. Rastelli, V. Rizzo, T. Santantonio, A. Scuteri, O. Sorbello, G. Squadrito, M. Subic, P. Toniutto, R. Vukotic
Add-on-peg-IFN improves HBSAG kinetics in patients long-term fully suppressed by nucleos(T)ide analogs
2012 P. Lampertico, F. Invernizzi, R. Soffredini, F. Facchetti, G. Lunghi, M. Viganò, M. Colombo
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H
2006 A. Cortelezzi, M. Viganò, V.R. Zilioli, N.N. Fantini, M.C. Pasquini, G. Lambertenghi-Deliliers, M. Colombo, P. Lampertico